progesterone, and dexamethasone coordinately and adversely regulate glucokinase and cAMP/PDE cascades in MIN6 ␤-cells. Am J Physiol Endocrinol Metab 286: E304-E310, 2004. First published October 14, 2003 10.1152/ajpendo.00210.2003.-Islet cells undergo major changes in structure and function to meet the demand for increased insulin secretion during pregnancy, but the nature of the hormonal interactions and signaling events is incompletely understood. Here, we used the glucose-responsive MIN6 ␤-cell line treated with prolactin (PRL), progesterone (PRG), and dexamethasone (DEX, a synthetic glucocorticoid), all elevated during late pregnancy, to study their effects on mechanisms of insulin secretion. DEX alone or combined with PRL and PRG inhibited insulin secretion in response to 16 mM glucose-stimulating concentrations. However, in the basal state (3 mM glucose), the insulin levels in response to DEX treatment were unchanged, and the three hormones together maintained higher insulin release. There were no changes of protein levels of GLUT2 or glucokinase (GK), but PRL or PRG treatment increased GK activity, whereas DEX had an inhibitory effect on GK activity. ␣-Ketoisocaproate (␣-KIC)-stimulated insulin secretion was also reduced by DEX alone or combined with PRL and PRG, suggesting that DEX may inhibit distal steps in the insulin-exocytotic process. PRL treatment increased the concentration of intracellular cAMP in response to 16 mM glucose, suggesting a role for cAMP in potentiation of insulin secretion, whereas DEX alone or combined with PRL and PRG reduced cAMP levels by increasing phosphodiesterase (PDE) activity. These data provide evidence that PRL and to a lesser extent PRG, which increase in early pregnancy, enhance basal and glucose-stimulated insulin secretion in part by increasing GK activity and amplifying cAMP levels. Glucocorticoid, which increases throughout gestation, counteracts only glucose-stimulated insulin secretion under high glucose concentrations by dominantly inhibiting GK activity and increasing PDE activity to reduce cAMP levels. These adaptations in the ␤-cell may play an important role in maintaining the basal hyperinsulinemia of pregnancy while limiting the capacity of PRL and PRG to promote glucose-stimulated insulin secretion during late gestation.
with enhanced ␤-cell proliferation, insulin synthesis, and glucose-induced insulin release (24, 26) . However, there are several other hormones that increase early during pregnancy that may participate in the regulation of islet function. Prolactin levels increase up to 10-fold in early pregnancy, progesterone increases fivefold, and glucocorticoid levels continue to rise throughout gestation, peaking during late pregnancy (2) . In vitro, progesterone counteracts the effects of lactogenic hormones on insulin secretion and islet ␤-cell division (25) . However, in vivo studies indicate that progesterone stimulates pancreatic cell proliferation but has no effect on insulin secretion (17, 18) .
Data accumulated thus far suggest that prolactin and placental lactogen upregulate islet function by 1) increased insulin synthesis; 2) increased glucose utilization, oxidation, and metabolism; and 3) increasing glucose-induced insulin release with a reduced glucose stimulation threshold (24, 26, 29, 30) . The mechanisms underlying these observations have received little attention. Recently, a role for cAMP production via activation of PKA on amplifying glucose-induced insulin secretion has been suggested (10) , which could play a role in pregnancy-induced insulin secretion. Many studies suggest that glucocorticoids inhibit insulin synthesis and glucose-stimulated insulin secretion by inhibiting the insulin-exocytotic process (13, 22) . The increase in maternal glucocorticoids during late pregnancy has been suggested to contribute to reduced glucose-stimulated insulin secretion (11) and may counteract the effect of prolactin; however, the mechanisms underlying this effect have not been studied. These studies suggest that prolactin and glucocorticoids may regulate islet function at different sites, but the mechanisms are not clear.
The goal of present study was to determine the mechanism(s) whereby prolactin, progesterone, and dexamethasone regulate ␤-cell function and how they work together to either augment or suppress insulin secretion. With use of the glucoseresponsive ␤-cell line MIN6, our results indicate that prolactin, and to a lesser extent progesterone, upregulate basal insulin release and glucose-stimulated insulin secretion primarily by increasing glucokinase activity. However, dexamethasone dominantly downregulates only glucose-stimulated insulin secretion from MIN6 cells, not only by reducing glucokinase activity but also by reducing exocytosis and by reducing cAMP levels via increased phosphodiesterase activity. This activity may in part help explain the basal hyperinsulinemia of pregnancy and possibly a reduced capacity for insulin secretion during late gestation. Cell culture. MIN6 ␤-cells were maintained and grown in DMEM containing 10% (vol/vol) heat-inactivated fetal bovine serum with 2 mM glutamine, 25 mM glucose, 50 M ␤-mercaptoethanol, 100 IU/ml penicillin, and 100 g/ml streptomycin in a humidified atmosphere at 37°C with 5% CO2. For determination of the effect of hormones, cells were cultured in the same medium but containing 5.5 mM glucose and supplemented with PRL, PRG, DEX, or all three hormones together at times and concentrations indicated in RESULTS. DEX was dissolved in 100% ethanol, the final concentration of ethanol was Ͻ0.1%, and an equivalent amount of ethanol was added to the controls. The culture medium was changed every 12 h when hormones were applied.
MATERIALS AND METHODS

Materials
Measurement of insulin secretion. To determine the effect of hormone treatment on acute insulin secretion, the cells were first washed twice with modified Krebs-Ringer bicarbonate (KRB) buffer (in mM: 125 NaCl, 5.6 KCl, 2.5 CaCl2, 2.5 MgCl2, 20 HEPES, pH 7.4, with 3 mM glucose and 0.1% BSA), followed by incubation for 1 h in this buffer at 37°C. The cells were then stimulated acutely with KRB supplemented with either basal glucose at 3 or 16 mM glucose or 10 mM ␣-ketoisocaproate (␣-KIC) at 37°C, and the medium was collected at the end of 1 h of stimulation. The medium was collected and stored at Ϫ20°C for subsequent insulin assay. Insulin concentration was measured by ELISA using the ALPCO kits.
Preparation of protein extracts. After hormone treatment and stimulation, cells were washed twice with ice-cold PBS and lysed in cold lysis buffer containing 1% Nonidet P-40, 150 mM NaCl, 1 mM EDTA, 1 mM Na3VO4, 1 mM NaF, 50 mM Tris, pH 7.4, 1 mM PMSF, 1 g/ml aprotinin, 1 g/ml leupeptin and 1 g/ml pepstatin. The lysates were collected and centrifuged for 15 min at 12,000 g. The pellets were discarded. The protein extract was stored at Ϫ20°C for Western blotting.
Immunoblotting. Equal amounts of protein (75 g) were subjected to 7 or 10% SDS-PAGE and transferred to PVDF membrane. After blocking with 5% fat-free milk, the membrane was incubated with GLUT2 antibody [1:1,000 in Tris-buffered saline plus Tween (TBS-T) with 5% fat-free milk] or glucokinase antibody (1:500 in TBS-T with 5% milk) overnight at 4°C. The membranes were washed extensively with TBS-T and incubated for 1 h with HRP-conjugated goat anti-rabbit IgG (1:10,000) and then washed with TBS-T. The bands were visualized by enhanced chemiluminesence (ECL; Amersham Pharmacia Biotech, Arlington heights, IL) according to the manufacturer's instructions.
Glucokinase activity assay. Glucokinase activity was measured as previously described (15, 23) . Briefly, the cells were washed once with ice-cold PBS and lysed with lysis buffer (in mM: 10 Tris, pH 7.0, 100 KCl, 15 EDTA, 600 sucrose, and 15 ␤-mercaptoethanol and 10 g/ml leupeptin, 1 mM benzamidine and 1 mM PMSF). After sonication for 10 s, the lysates were centrifuged at 10,000 g for 15 min at 4°C. The supernatants were collected, and protein concentration was measured using the Bio-Rad assay reagent. Glucose-phosphorylating activity was measured spectrophotometrically in 10,000-g supernatant fractions of cell extracts at 37°C in the presence of 100 mM and 0.5 mM glucose as described (15) . The phosphorylation capacity obtained at 0.5 mM glucose is considered the hexokinase activity, whereas the subtraction of the activity measured at 0.5 mM glucose from the activity measured at 100 mM glucose is considered the glucokinase activity of the extract.
cAMP and phosphodiesterase activity assay. cAMP levels were measured after incubation with desired hormones in the presence or absence of the phosphodiesterase (PDE) inhibitor IBMX (500 M). The cells were washed and incubated with KRB buffer for 1 h and then incubated with KRB buffer with 16 mM glucose for 1 h with or without IBMX. Excess culture medium was aspirated, and the cells were lysed with reagent materials supplied with the ELISA kit. The intracellular cAMP concentration was measured by ELISA (Amersham Pharmacia Biotech).
PDE activity was measured as described previously (5, 28) . Briefly, 100 l of cell lysates were incubated for 10 min at 30°C in a total volume of 300 l containing 50 mM HEPES, pH 7.4, 0. Statistical analysis. All results are expressed as means Ϯ SE. Statistics were determined using ANOVA, followed by contrast test with Tukey or Dunnett error protection. Differences were considered significant at P Ͻ 0.05.
RESULTS
PRL and PRG increase basal insulin secretion and DEX dominantly inhibits glucose-stimulated insulin secretion in MIN6 cells.
To compare the individual effects of PRL, PRG, and DEX on basal insulin secretion, MIN6 ␤-cells were cultured with 0-1,000 ng/ml PRL or DEX or 0-1,000 nM PRG, and insulin accumulation was determined after 24 h. Both PRL at 50 ng/ml and PRG at 50 nM increased insulin levels significantly (P Ͻ 0.05, Fig. 1 ). The maximum effect of PRL was achieved at a concentration of 500 ng/ml, and PRG was achieved at 500 nM ( Fig. 1) . DEX treatment reduced basal insulin accumulation slightly but significantly, beginning at 100 ng/ml (P Ͻ 0.05).
To examine how these hormones affected glucose-stimulated insulin secretion acutely, MIN6 cells were treated with each hormone alone or combined for 6, 12, 24, or 48 h and challenged with low (3 mM) or high (16 mM) glucose for 1 h (Fig. 2, A and B) . PRL significantly increased 3 mM glucosestimulated insulin release, reaching its peak effect at 24 h of hormone exposure ( Fig. 2A , P Ͻ 0.001). Interestingly, although PRG and PRL both increased basal insulin release over 24 h (Fig. 1) , the ability of PRG-treated cells to acutely increase insulin secretion in response to 3 mM glucose was much less compared with PRL ( Fig. 2A , P Ͻ 0.01). DEX treatment had no significant effect on 3 mM glucose-stimulated insulin release. In cells treated with all three hormones (Mix), 3 mM glucose-stimulated insulin release was significantly increased at all time points (P Ͻ 0.01), suggesting that PRG and PRL together augment insulin levels in response to low glucose challenge, even in the presence of DEX.
At higher (16 mM) glucose concentrations, a significant increase in insulin release in response to PRL and PRG was seen at all time points from 6 h on ( Fig. 2B , P Ͻ 0.01), whereas DEX inhibited insulin secretion significantly at all time points (P Ͻ 0.01). In contrast to 3 mM glucose, when the three hormones were added together, insulin release at 16 mM glucose was inhibited beginning at the 12-h time point (Fig.  2B) , suggesting that DEX has little effect at 3 mM glucose but exerts a dominant negative effect on insulin secretion over the other hormones when the cells are challenged at 16 mM glucose.
PRL and PRG increase glucokinase activity, but DEX dominantly inhibits glucokinase activity in MIN6 cells. It is well known that glucose oxidation in mitochondria increases the ATP/ADP ratio, thereby inducing a closure of the ATP-dependent K ϩ channel, leading to insulin secretion (10) . Because glucokinase is one of the key regulatory enzymes in control of glucose metabolism in ␤-cells (6, 10), we measured glucokinase protein and activity levels in hormone-treated cells. There were no differences in glucokinase protein levels before or after treatment with any hormone (data not shown). However, as shown in Fig. 3 , PRL treatment significantly increased glucokinase activity at all time points and maximally at 24 h (P Ͻ 0.05). PRG also increased glucokinase activity (P Ͻ 0.05) but to a lesser extent than in PRL-treated cells, reaching maximal levels at 12 h. Similar to insulin secretion, DEX treatment inhibited glucokinase activity in MIN6 cells with prolonged incubation, beginning at 6 h (P Ͻ 0.05). When the cells were treated with all three hormones together, glucokinase activity went down in a manner similar to DEX alone (P Ͻ 0.05), suggesting a dominant negative effect of DEX on glucokinase activity. We also measured GLUT2 protein levels in hormone-treated MIN6 cells. GLUT2 protein level was slightly increased after 6-h DEX treatment (P Ͼ 0.05) and then returned to normal levels by 48 h (data not shown). PRL and PRG had no effect on GLUT2 protein level even after 48 h of incubation.
To determine the contribution of glucokinase in regulation of insulin secretion in hormone-treated cells, we incubated hormone-treated cells with the glucokinase inhibitor 5-thio-Dglucose under low and high glucose concentrations (27) . Consistent with previous studies, 5-thio-D-glucose had much less inhibitory effect on insulin release at 3 mM compared with 16 mM glucose (Fig. 4) . With the exception of PRL-treated cells, ␣-KIC-induced insulin secretion in hormone-treated cells. ␣-KIC is a leucine derivative that increases ␤-cell stimulus secretion coupling by generating ATP distally via oxidative phosphorylation and by direct inhibition of potassium-dependent ATP (K ATP ) channels to increase insulin secretion (1). We used ␣-KIC to test whether PRL, PRG, or DEX had any additional effects on this distal mechanism for increasing insulin secretion. As shown in Fig. 5 , there was no significant difference in ␣-KIC-induced insulin secretion in either PRL-or PRG-treated cells compared with nonhormone-treated cells. However, in DEX-and Mix hormone-treated MIN6 cells, after a 12-h incubation, ␣-KIC-stimulated insulin secretion was lower compared with ␣-KIC-treated control cells, reaching a maximum at 48 h.
DEX counteracts PRL effects through increased PDE activity. cAMP is known to play an important role in the regulation of insulin secretion in response to glucose via activation of PKA (9, 10) . At low glucose concentrations, the augmentation of cAMP content has very little if any effect on insulin secretion. However, in response to high glucose, cAMP can amplify or potentiate glucose-stimulated insulin secretion (10) . We sought to determine the role of cAMP in glucose-stimulated insulin secretion in hormone-treated cells. After 24 h of treatment with different hormones and 1 h of stimulation with 16 mM glucose, intracellular cAMP levels were significantly increased in PRL-treated cells (Fig. 6A , P Ͻ 0.05). There was no change in cAMP concentration in PRG-treated cells. However, in DEX-treated cells, and to a lesser extent in Mix-treated cells, cAMP levels were lower by nearly 50% compared with control cells (P Ͻ 0.05).
To examine the possible underlying mechanisms for cAMP regulation in response to hormone treatment, we used the PDE inhibitor IBMX (500 M), which inhibits cAMP breakdown, thereby allowing the measurement of cAMP production in the absence of catabolism. MIN6 cells were treated with hormones as above and stimulated for 1 h with 16 mM glucose and IBMX (Fig. 6B) . In all cells, IBMX increased the cAMP concentration 10-to 50-fold. In PRL-treated cells, IBMX had no significant effect on intracellular cAMP content compared with control cells. The lack of change using the PDE inhibitor suggests that the increase in cAMP in PRL-treated cells could be due to inhibition of PDE as well as increased cAMP production. In Fig. 7 , PDE activity was determined in PRL-treated cells and was unchanged. In PRG-treated cells, cAMP levels were not significantly changed with 16 mM glucose with or without IBMX compared with control cells. Because PDE activity in PRG-treated cells shown was increased (Fig. 7) , this suggests that PRG may have stimulated an increase in cAMP production offset by greater PDE activity. DEX or the combination of hormones reduced cAMP levels but was increased significantly (P Ͻ 0.05) in the presence of PDE inhibitor IBMX. 6 . Effect of hormone treatment on glucose-induced cAMP levels in MIN6 cells. Cells were incubated for 24 h in DMEM medium containing 5.5 mM glucose, supplemented with PRL (500 ng/ml), PRG (100 nM), DEX (100 nM), or all 3 hormones (Mix) together. One hour before lysis, the glucose concentration of medium was increased to 16 mM. Cells were also treated without (A) or with (B) IBMX. The medium was aspirated, and cells were washed twice. cAMP levels were measured as described in MATERIALS AND METHODS. Each sample was tested in duplicate. Values are means Ϯ SE from 4 separate experiments. *P Ͻ 0.05 vs. corresponding control value.
DISCUSSION
It is well known that glucocorticoids can impair the function of the endocrine pancreas; however, the cellular mechanism(s) whereby prolactin, progesterone, and dexamethasone work together to either stimulate or suppress insulin secretion in the islet has received relatively little attention. It has been reported that, during pregnancy, prolactin and progesterone increase ␤-cell mass and insulin gene expression, and, synergistically with glucose, stimulate insulin production (7, 20) . In the present study, we show that prolactin has a marked effect on increasing both basal and glucose-induced insulin secretion from MIN6 cells, whereas progesterone alone had a stimulatory effect but to a lesser extent. These results are consistent with earlier studies performed on isolated islets (24, 26) and support the concept that placental lactogen(s) upregulate ␤-cell insulin secretion during pregnancy. Both in vivo and organ culture experiments suggest that short-term (Ͻ12 h) progesterone treatment enhances insulin secretion during pregnancy (3, 16) . However, Sorenson et al. (25) found that 3 days of progesterone treatment had an inhibitory effect on insulin secretion in incubated neonatal rat islets. The reasons for these differences are not clear but could be due to differences between cultured fetal islets and the mouse-derived MIN6 cells. MIN6 cells are mature, well-differentiated cells that maintain a robust response to glucose in culture (12) . In addition, MIN6 cells, although they are not true islets, maintain their response to a number of physiologically relevant secretagogues, including cAMP, but may differ from neonatal islets maintained in culture.
An important finding of the present study is that dexamethasone, alone or in combination with prolactin and progesterone, inhibited insulin secretion in response to 16 mM glucosestimulating concentrations. However, in the basal state (3 mM glucose), the insulin levels in response to dexamethasone treatment were unchanged, and three hormones together maintained higher insulin release. These data suggest that the adaptive response to dexamethasone primarily affects only glucose-stimulated insulin secretion and counteracts the effects of prolactin and progesterone. Our results show that a major mechanism whereby dexamethasone suppresses insulin secretion involves a decrease in glucokinase activity. Glucokinase is the major rate-limiting enzyme of glucose metabolism in the ␤-cell and serves as a glucose sensor in regulating insulin secretion. Previous studies showed that glucose utilization and oxidation are increased in islets during pregnancy (31). We found that prolactin and progesterone increased glucokinase activity without a change in the level of expression of the protein, whereas dexamethasone suppressed glucokinase activity. It is very possible that glucokinase activity can be induced by changes in the conformational state of the enzyme, which would not be picked up by measuring the protein level by Western blotting. To determine the contribution of glucokinase to the responsiveness to glucose, the glucokinase inhibitor 5-thio-D-glucose was used in basal and glucose-stimulated cells. Basal and 16 mM glucose-stimulated insulin release in prolactin-treated cells was still higher than in control cells at the same glucose concentration using 5-thio-D-glucose, whereas in progesterone-and dexamethasone-treated cells the glucokinase inhibitor reversed the insulin release to control levels. These results suggest that progesterone and dexamethasone may operate through glucokinase to control insulin release but that prolactin may have more than one mechanism in addition to glucokinase activation to enhance insulin secretion. For example, prolactin treatment enhances the production of cAMP levels in response to glucose, and this may be an important factor underlying the potentiation of glucose-stimulated insulin secretion.
␣-KIC was used to determine whether these hormones act on a distal pathway to stimulate insulin secretion by enhancing mitochondrial ATP production and possibly by triggering a release of cytosolic calcium to close K ATP channels of the plasma membrane (8) . The ability of ␣-KIC to stimulate this pathway for insulin release was unchanged in prolactin-and progesterone-treated cells; however, dexamethasone alone or in combination with prolactin and progesterone dominantly suppressed ␣-KIC-mediated insulin release. These data suggest that, in addition to reducing glucokinase activity, dexamethasone alone may also interfere with ␤-cell stimulus secretion coupling either by reduced generation of mitochondrial ATP or perhaps by modulation of the K ATP channels. Reduced insulin synthesis cannot account for the inhibition of ␣-KIC-induced insulin secretion, because dexamethasone increases the proinsulin mRNA and insulin content in islets (13, 19, 30) .
It is well established that glucose stimulates insulin release through a K ATP channel-dependent triggering pathway and by a K ϩ channel-independent amplifying pathway (4, 10) . The triggering pathway is well characterized and includes entry of glucose, glucose oxidation, and increased ATP/ADP ratio, closure of K ATP channels, opening of Ca 2ϩ channels, increases in cytoplasmic free Ca 2ϩ , and activation of the exocytotic process. The amplifying pathway includes Ca 2ϩ -dependent and Ca 2ϩ -independent augmentation pathways. It has been suggested that glucose's effect on augmenting insulin secretion is activated by increases in cellular cAMP that potentiate insulin secretion through an increase in PKA and small G protein pathway (10) . The mechanism may involve an increase in increased rates of phosphorylation of ion channels, leading to accelerated exoctyosis (10) . Our results show that, similar to a previous observation in islets (29) , 24 h of prolactin treatment increased cAMP content 86% in MIN6 cells at high glucose concentrations, whereas progesterone had no effect on cAMP levels compared with control cells incubated under similar glucose concentrations. Our results extend these observations to show that dexamethasone dominantly suppresses cAMP concentration alone and in combination with prolactin and progesterone. These data, together with a previous study show- Fig. 7 . Effect of hormone treatment on phosphodiesterase (PDE) activity in MIN6 cells. Cells were incubated for 24 h with PRL (500 ng/ml), PRG (100 nM), DEX (100 nM), or all 3 hormones (Mix) together. Cells were lysed, and PDE activity was measured as described in MATERIALS AND METHODS. Values are means Ϯ SE from 4 separate experiments. *P Ͻ 0.05 vs. control.
ing a strong linear correlation between cAMP and the rate of glucose oxidation in islets (29) , suggest that reduced metabolism of glucose via suppressed glucokinase activity may lower levels of cAMP and could be a major contributor to dexamethasone's suppressive effects on prolactin-induced insulin secretion. Moreover, it has been reported that the inhibitory effects of dexamethasone on insulin secretion can be reversed by incubation with cAMP analogs (13, 21) , suggesting that dexamethasone may inhibit both the triggering and the amplifying pathways for glucose-mediated insulin release in the islet. The stimulatory effects of progesterone on insulin release may, however, be different from those of prolactin; that is, we found no increase in cAMP levels compared with control cells.
The steady-state levels of cAMP are regulated by the relative activity of adenylate cyclase and phosphodiesterase activity (9, 14) . Our results show that, in the presence of the phosphodiesterase inhibitor IBMX, the increase in cAMP concentration in prolactin-treated cells was reduced to control levels. These data imply that prolactin enhances the net production of cAMP primarily by increasing adenylate cyclase activity. This was confirmed by measuring phosphodiesterase activity directly in MIN6 cells, which was unchanged in response to prolactin treatment. Progesterone on the other hand, increased cAMP levels in the presence of IBMX, and phosphodiesterase activity was increased in progesterone-treated cells. These data imply that progesterone increases cAMP synthesis and catalysis equally, and thus cAMP levels remained unchanged.
In our study, we found that 24-h incubation with dexamethasone reduced cAMP levels nearly 50% in MIN6 cells. After inhibition of phosphodiesterase activity with IBMX, cAMP levels increased beyond control cells. This suggests that an increment in phosphodiesterase activity in glucocorticoidtreated cells may be proportionally higher than biosynthesis via adenylate cyclase to lower cAMP levels. Direct measurement of phosphodiesterase activity confirmed this observation. This mechanism also applies to the inhibitory effects of dexamethasone on prolactin and progesterone. Incubation with dexamethasone in combination with prolactin and progesterone reduced cAMP level nearly 40% in MIN6 cells, associated with increased phosphodiesterase activity. Thus, under these in vitro conditions, dexamethasone dominantly reduces cAMP levels in part due to increased phosphodiesterase activity to impair insulin secretion.
In summary, our study confirms the hypothesis that elevated prolactin and progesterone coordinately upregulate insulin secretion, whereas glucocorticoids counter these effects only at higher glucose concentrations in MIN6 cells. An increase in glucokinase activity is one of the main mechanisms for upregulating insulin secretion by prolactin and progesterone under basal conditions. Dexamethasone counteracts the upregulating effects of prolactin and progesterone at high glucose concentration by dominantly inhibiting glucose-stimulated glucokinase activity and by affecting the distal exocytotic process by increasing phosphodiesterase activity to reduce cAMP levels. These changes were observed primarily at high rather than basal glucose concentrations, which suggests that these adaptations in the ␤-cell could play an important role in maintaining the basal hyperinsulinemia of pregnancy while limiting the capacity of prolactin and progesterone to promote glucosestimulated insulin secretion during late gestation. It is possible that the counteracting effects of glucocorticoids may be an important factor(s) underlying the inadequate insulin-secretory response that characterizes women with impaired glucose tolerance during pregnancy.
